{
    "nctId": "NCT00986609",
    "briefTitle": "MUC1 Vaccine for Triple-negative Breast Cancer",
    "officialTitle": "Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "Proportion of patients showing a positive anti-MUC1 antibody response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* AJCC stage I-III infiltrating adenocarcinoma of the breast who have completed standard adjuvant or neoadjuvant therapy (surgery, radiation, biologic therapy, chemotherapy) for TNBC (ER-, PR-, HER-2/neu-)\n* Patients who have completed standard therapy for triple-negative inflammatory BC are eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Absolute neutrophil count \\>= 1,000/mm\\^3\n* Hemoglobin \\>= 10.0 g/dl\n* Platelet count \\>= 100,000/mm\\^3\n* Total bilirubin must be within normal limits\n* Transaminases (aspartate aminotransferase \\[AST\\] and/or alanine aminotransferase \\[ALT\\]) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is =\\< ULN\n* Alkaline phosphatase may be up to 4 x ULN if transaminases are =\\< ULN\n* Normal creatinine and blood urea nitrogen (BUN); if abnormal, calculated creatinine clearance must be \\>= 60 mg/dL\n* Human immunodeficiency virus (HIV)(-), antinuclear antibody (ANA)(-), hepatitis panel (-), normal thyroid function tests; these tests will be performed at the discretion of the Investigator if warranted by history or clinical presentation\n* Patients must be disease-free of prior invasive malignancies for \\>= 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* All patients must have completed surgery with sentinel and/or axillary lymph node dissection according to participating institutional guidelines\n* All patients must have completed adjuvant radiation therapy according to participating institutional guidelines\n* All patients must have completed either adjuvant or neoadjuvant chemotherapy according to participating institutional guidelines; the choice of chemotherapy is at the discretion of the treating physician\n* Women of childbearing potential must have a negative pregnancy test and must be willing to consent to using an accepted and effective barrier form method of contraception during participation in the study and for a reasonable period thereafter\n* Patients must provide written informed consent\n\nExclusion Criteria:\n\n* Known metastatic BC\n* Radiotherapy, chemotherapy, biologic therapy, or other investigational therapy within the preceding 4 weeks\n* Previous splenectomy or radiotherapy to spleen\n* Coexisting or previous malignancies except carcinoma in situ of the cervix or basal cell carcinoma of the skin\n* Active or uncontrolled infection\n* Psychiatric, addictive, or any disorder that compromises the ability to give informed consent to participate in or to comply with the requirements of the study\n* Concurrent systemic corticosteroid treatment - must be off all steroids for at least 4 weeks prior to vaccine administration\n* Any condition or behavior that in the judgment of the Investigator, would compromise the patient's ability to participate in the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}